🚀 VC round data is live in beta, check it out!
Xlife Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Xlife Sciences and similar public comparables like Kinea Oportunidades Real Estate FII, Brockhaus Technologies, Spectral Capital, Arbona and more.
Xlife Sciences Overview
About Xlife Sciences
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
Founded
2019
HQ
Employees
17
Website
Financials (FY)
EV
$241M
Xlife Sciences Financials
Xlife Sciences reported last fiscal year revenue of $1M and EBITDA of $52M.
In the same fiscal year, Xlife Sciences generated $702K in gross profit, $52M in EBITDA, and $44M in net income.
Xlife Sciences P&L
In the most recent fiscal year, Xlife Sciences reported revenue of $1M and EBITDA of $52M.
Xlife Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $702K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 66% | XXX | XXX | XXX |
| EBITDA | — | XXX | $52M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 4851% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (2317%) | XXX | XXX | XXX |
| Net Profit | — | XXX | $44M | XXX | XXX | XXX |
| Net Margin | — | XXX | 4106% | XXX | XXX | XXX |
| Net Debt | — | — | $75M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Xlife Sciences Stock Performance
Xlife Sciences has current market cap of $166M, and enterprise value of $241M.
Market Cap Evolution
Xlife Sciences' stock price is $28.73.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $241M | $166M | 3.0% | XXX | XXX | XXX | $7.59 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialXlife Sciences Valuation Multiples
Xlife Sciences trades at 226.1x EV/Revenue multiple, and 4.7x EV/EBITDA.
Xlife Sciences Financial Valuation Multiples
As of April 18, 2026, Xlife Sciences has market cap of $166M and EV of $241M.
Equity research analysts estimate Xlife Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Xlife Sciences has a P/E ratio of 3.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $166M | XXX | $166M | XXX | XXX | XXX |
| EV (current) | $241M | XXX | $241M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 226.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 4.7x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (9.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 343.5x | XXX | XXX | XXX |
| P/E | — | XXX | 3.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (435.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Xlife Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Xlife Sciences Margins & Growth Rates
Xlife Sciences' revenue in the last fiscal year declined by (16%).
Xlife Sciences' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.5M for the same period.
Xlife Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (16%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 4851% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 93% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 230% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 2383% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Xlife Sciences Public Comps
See public comps and valuation multiples for other PE & VC comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Xlife Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Kinea Oportunidades Real Estate FII | XXX | XXX | XXX | XXX | XXX | XXX |
| Brockhaus Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Spectral Capital | XXX | XXX | XXX | XXX | XXX | XXX |
| Arbona | XXX | XXX | XXX | XXX | XXX | XXX |
| Rbr Log FII | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xlife Sciences M&A Activity
Xlife Sciences acquired XXX companies to date.
Last acquisition by Xlife Sciences was on XXXXXXXX, XXXXX. Xlife Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Xlife Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialXlife Sciences Investment Activity
Xlife Sciences invested in XXX companies to date.
Xlife Sciences made its latest investment on XXXXXXXX, XXXXX. Xlife Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Xlife Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Xlife Sciences
| When was Xlife Sciences founded? | Xlife Sciences was founded in 2019. |
| Where is Xlife Sciences headquartered? | Xlife Sciences is headquartered in Switzerland. |
| How many employees does Xlife Sciences have? | As of today, Xlife Sciences has over 17 employees. |
| Is Xlife Sciences publicly listed? | Yes, Xlife Sciences is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Xlife Sciences? | Xlife Sciences trades under XLS ticker. |
| When did Xlife Sciences go public? | Xlife Sciences went public in 2022. |
| Who are competitors of Xlife Sciences? | Xlife Sciences main competitors are Kinea Oportunidades Real Estate FII, Brockhaus Technologies, Spectral Capital, Arbona. |
| What is the current market cap of Xlife Sciences? | Xlife Sciences' current market cap is $166M. |
| What is the current revenue of Xlife Sciences? | Xlife Sciences' last fiscal year revenue is $1M. |
| What is the current EV/Revenue multiple of Xlife Sciences? | Current revenue multiple of Xlife Sciences is 226.1x. |
| Is Xlife Sciences profitable? | No, Xlife Sciences is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.